Compare GCBC & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GCBC | FHTX |
|---|---|---|
| Founded | 1889 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 374.8M | 332.2M |
| IPO Year | 1998 | 2020 |
| Metric | GCBC | FHTX |
|---|---|---|
| Price | $23.70 | $4.87 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $11.50 |
| AVG Volume (30 Days) | 10.5K | ★ 131.3K |
| Earning Date | 04-20-2026 | 05-13-2026 |
| Dividend Yield | ★ 1.70% | N/A |
| EPS Growth | ★ 26.21 | 25.32 |
| EPS | ★ 1.13 | N/A |
| Revenue | $4,117,000.00 | ★ $30,909,000.00 |
| Revenue This Year | N/A | $7.81 |
| Revenue Next Year | N/A | $17.72 |
| P/E Ratio | $20.78 | ★ N/A |
| Revenue Growth | 11.06 | ★ 36.75 |
| 52 Week Low | $20.62 | $3.27 |
| 52 Week High | $26.04 | $6.95 |
| Indicator | GCBC | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 60.26 | 46.82 |
| Support Level | $22.79 | $4.42 |
| Resistance Level | $25.09 | $5.85 |
| Average True Range (ATR) | 0.59 | 0.28 |
| MACD | 0.12 | 0.03 |
| Stochastic Oscillator | 75.22 | 58.82 |
Greene County Bancorp Inc is a holding firm. Its primary business involves overseeing and directing the business of The Bank of Greene County and monitoring its cash position. Through its directly and indirectly owned subsidiaries, the company engages in attracting retail deposits, along with funds generated from operations and borrowings, predominantly in one to four-family residential mortgage loans, commercial real estate mortgage loans, consumer loans, home equity loans, and commercial business loans. It also serves local municipalities' banking needs and operates a real estate investment trust.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.